Home Featured Page 9

Featured

Latest

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding

From Individualism to Connection: How Psychedelics and Group Therapy Can Heal Our Collective Crisis

Somatic Therapy and Psychedelics: How Body-Centered Approaches Are Revolutionizing Trauma Treatment

Psychedelics Today Live Podcast

The Enneagram: A Dynamic Framework for Self-Discovery

Psychedelics and Creativity, Endo-Tripping, and the Origins of Life on Earth

Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This...

Pioneering Psychedelic Policy: Nevada’s Senate Bill 242 and Beyond

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Johanna

Jungian Psychology, Psychedelics, and the Multiplicity of Self

Psychedelic Funding Update: Q2 2024

1...8910...275 Page 9 of 275

EDITOR PICKS

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding

From Individualism to Connection: How Psychedelics and Group Therapy Can Heal Our Collective Crisis

Somatic Therapy and Psychedelics: How Body-Centered Approaches Are Revolutionizing Trauma Treatment

Psychedelics Today Live Podcast

The Enneagram: A Dynamic Framework for Self-Discovery

Psychedelics and Creativity, Endo-Tripping, and the Origins of Life on Earth

Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This...

Pioneering Psychedelic Policy: Nevada’s Senate Bill 242 and Beyond

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Johanna

Jungian Psychology, Psychedelics, and the Multiplicity of Self

Psychedelic Funding Update: Q2 2024

EDITOR PICKS

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY